Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355407 · ClinicalTrials.gov registry record · NA
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT00355407 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 31 participants.
The verdict
NCT00355407, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to help raise red blood cell levels without blood transfusions.
Interventions
- DRUG Darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00355407
The ClinicalTrials.gov registry entry for NCT00355407 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Darbepoetin alfa is the first listed.
NCT00355407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00355407 about?
NCT00355407 is a clinical study titled "Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation". The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to help raise red blood cell levels without blood transfusions.
What is the current status of trial NCT00355407?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2006-06. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00355407?
The interventions under investigation include: Darbepoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00355407?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.